{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:54:12Z","timestamp":1791150852019,"version":"4.1.0"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,10,23]],"date-time":"2006-10-23T00:00:00Z","timestamp":1161561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2007,1]]},"abstract":"\n Summary<\/jats:title>\n <\/jats:sec>\n \n Background<\/jats:title>\n Functional abdominal pain disorders (FAPD) are common in school\u2010aged children; however, there is no reliable treatment.<\/jats:p>\n <\/jats:sec>\n \n Aim<\/jats:title>\n \n To determine the efficacy of\n Lactobacillus rhamnosus<\/jats:italic>\n GG (LGG) for treating FAPD in children.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A total of 104 children who fulfilled the Rome II criteria for functional dyspepsia (FD), or irritable bowel syndrome (IBS), or functional abdominal pain (FAP) were enrolled in a double\u2010blind, randomized controlled trial in which they received LGG (\n n<\/jats:italic>\n \u2003=\u200352), or placebo (\n n<\/jats:italic>\n \u2003=\u200352) for 4\u2003weeks.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n For the overall study population, those in the LGG group were more likely to have treatment success (no pain) than those in the placebo group (25% vs. 9.6%, relative benefit (RB) 2.6, 95% confidence interval (CI): 1.05\u20136.6, number needed to treat (NNT) 7, 95% CI: 4\u2013123). For children with IBS (\n n<\/jats:italic>\n \u2003=\u200337), those in the LGG group were more likely to have treatment success than those in the placebo group (33% vs. 5%, RB 6.3, 95% CI: 1.2\u201338, NNT 4, 95% CI: 2\u201336) and reduced frequency of pain (\n P<\/jats:italic>\n \u2003=\u20030.02), but not pain severity (\n P<\/jats:italic>\n \u2003=\u20030.10). For the FD group (\n n<\/jats:italic>\n \u2003=\u200320) and FAP group (\n n<\/jats:italic>\n \u2003=\u200347), no differences were found.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n The LGG appears to moderately increase treatment success, particularly among children with IBS.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/j.1365-2036.2006.03175.x","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T07:52:27Z","timestamp":1279871547000},"page":"177-184","source":"Crossref","is-referenced-by-count":204,"title":["A randomized double\u2010blind placebo\u2010controlled trial of\n Lactobacillus<\/i>\n GG for abdominal pain disorders in children"],"prefix":"10.1111","volume":"25","author":[{"given":"A.","family":"GAWRO\u0143SKA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"DZIECHCIARZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"HORVATH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"SZAJEWSKA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,10,23]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.50.3.429"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1993.tb12728.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.45.2008.ii60"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.08.063"},{"key":"e_1_2_7_6_2","first-page":"CD003017","article-title":"Pharmacological interventions for recurrent abdominal pain (RAP) in childhood","volume":"1","author":"Huertas\u2010Ceballos A","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_7_2","volume-title":"Joint FAO\/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk With Live Lactic Acid Bacteria","author":"FAO\/WHO","year":"2001"},{"key":"e_1_2_7_8_2","first-page":"77","article-title":"Traitement des colopathies fonctionnelles\u2010Essai en double aveugle de l'ultra\u2010levure. (Treatment of irritable bowel syndrome with Saccharomyces boulardii\u2010a double\u2010blind, placebo controlled study)","volume":"12","author":"Maupas JL","year":"1983","journal-title":"M\u00e9dicine et Chirurgie Digestives"},{"key":"e_1_2_7_9_2","first-page":"1579","article-title":"Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double\u2010blind, cross\u2010over trial","volume":"91","author":"Halpern GM","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.02015.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200110000-00004"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000129271.98814.e2"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01543.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02579.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.3109\/02813438909103666"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.06.005"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.11.050"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2005.05.015"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2005.05.011"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(90)90018-9"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.058"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.309.6957.780"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-2244(00)89085-8"},{"key":"e_1_2_7_24_2","first-page":"660","article-title":"Drug treatment of functional dyspepsia (a systematic analysis of trial methodology with recommendations for design of future trials)","volume":"91","author":"Veldhuyzen van Zanten SJ","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00086-8"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7347.1193"}],"container-title":["Alimentary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2006.03175.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2006.03175.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T17:03:13Z","timestamp":1697216593000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2006.03175.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,23]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.1111\/j.1365-2036.2006.03175.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2006.03175.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1066065.519035","asserted-by":"object"}]},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,23]]}}}